MDM2: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Matt Routh (talk | contribs) No edit summary |
Matt Routh (talk | contribs) No edit summary |
||
| Line 12: | Line 12: | ||
[[Image:800px-Signal transduction v1.png|Apoptosis signal pathway|400 px|thumb]] | [[Image:800px-Signal transduction v1.png|Apoptosis signal pathway|400 px|thumb]] | ||
MDM2 is an active inhibitor of the p53 anti-tumorgenesis protein. When MDM2 is atached p53 is unable to release transcription factors that code for apoptosis or halting of the cell cycle. The full cell signaling pathway is very complex, but MDM2 overproduction has been shown to be connected to cancer activity.[1] Genetic amplification of MDM2 has been shown in breast, glioma, pancreaticadenocarcinoma, leucemias, Hodgkin's and nonhodgkin's lymphomas and other various cancers. [1] This broad observation outlines the importance of determining MDM2's role in tumer-genesis and how the process can be treated. | MDM2 is an active inhibitor of the p53 anti-tumorgenesis protein. When MDM2 is atached p53 is unable to release transcription factors that code for apoptosis or halting of the cell cycle. The full cell signaling pathway is very complex, but MDM2 overproduction has been shown to be connected to cancer activity.[1] Genetic amplification of MDM2 has been shown in breast, glioma, pancreaticadenocarcinoma, leucemias, Hodgkin's and nonhodgkin's lymphomas and other various cancers. [1] This broad observation outlines the importance of determining MDM2's role in tumer-genesis and how the process can be treated. | ||
==Experimental Research== | |||
Early work in the field of MDM2 overproduction in tumor cells was done by Raphael E. Pollok et. al. | |||
==Reference== | ==Reference== | ||
